Client Testimonials

Nevan Charles Elam, J.D., Chairman and CEO, AntriaBio, Inc. (OTCQB: ANTB)

“We began working with Josh Berg and Aaron Gorin of Berg Capital Markets, LLC in May 2015, and they have already been instrumental in helping us develop our outreach approach to institutional investors and provide valuable input on our corporate strategy. Both Josh and Aaron have been extremely thorough in learning the nuances of AntriaBio’s history and technology platform to help us determine who, how, and when to target. Josh’s vast industry knowledge and deep relationships with relevant institutional investors coupled with Aaron’s analytical skills and grasp of capital markets provide AntriaBio with the precise investor relations expertise we have been seeking. We look forward to continuing our collaborative relationship with Berg Capital Markets as AntriaBio continues to grow and mature.”

Robert Newell,
Chief Financial Officer, Dextera (DXTR)

It is a privilege to recommend and endorse the work of Josh Berg and Nisha Hirani, MD of Berg Capital Markets, LLC. Josh and Nisha have the experience and the talent to be valued business partners for Life Science companies. They are professional experts in developing and communicating effective positioning in the public capital markets. They know the investment community and understand what shareholders and prospective shareholders want to see in investor communications and presentations. They are effective in targeting the right investor audience that is in-line with the market cap and positioning of their client companies. They leverage social media in a thoughtful and cost-effective way. They have a sense of urgency, pay attention to detail, and have a shared enthusiasm for their work. I highly recommend Josh and Nisha of Berg Capital Markets, LLC.

Julian Nikolchev,
President and Chief Executive Officer, Dextera (DXTR)

It has been a pleasure working with Josh Berg and Dr. Nisha Hirani as our principal capital markets and investor relations consultants. Their support, dedication, creativity and drive was demonstrated repeatedly during our time working together. Josh developed, directed, and successfully executed our IR program at Dextera that included investor outreach to his extensive network. In addition, Dr. Hirani led a highly effective social media program.  As a result, we were able to accomplish our goals of reaching a new and broader group of investors as well as developing a strong social media presence. I highly recommend both Josh and Dr. Hirani as two professionals that are driven, knowledgeable, efficient, and an absolute pleasure with whom to work! 

Barry D. Quart, Pharm.D.
, Chief Executive Officer and Director, Heron Therapeutics, Inc. (NASDAQ: HRTX)

Berg Capital Markets, LLC is a trusted partner to Heron Therapeutics (HRTX). It’s my pleasure to endorse the firm. Partners Josh Berg and Aaron Gorin have taken the time to learn our company and industry in detail. Leveraging its institutional investor relationships, analytics, and work ethic, the firm has added clear value to Heron.


Brian Culley,
CEO, Mast Therapeutics, Inc. (NYSEMKT:MSTX)

“I am pleased to provide my highest recommendation for Josh Berg of Berg Capital Markets for capital markets and investor relations consulting. I hired Josh in January 2013 and have been extremely pleased with his performance and contributions. Josh helped to attract sizeable new investors to Mast Therapeutics (MSTX) and was instrumental in connecting us with a national distribution of high-quality institutional equity managers and high net worth investors, many of whom continue to follow our Company. Josh clearly has earned the trust and respect of many large and small equity investment managers. And as someone who has worked with a number of investor relations firms, I found Berg Capital Markets to be differentiated by virtue of the amount of time Josh took to understand the nuances of our drug development programs and corporate strategy. In addition, Josh possesses broad industry knowledge and brings that breadth to bear with critical strategic thinking and practical tactical planning. In short, Josh provides uncommonly attentive and insightful service with unassailable ethics. Josh is a trusted partner to Mast Therapeutics and a pleasure to work with.”

Dirk van den Boom, PhD,
President & CEO, Sequenom, Inc. (SQNM)

Berg Capital Markets, LLC is a long-term, trusted partner to Sequenom (SQNM). We leverage the firm's institutional investor relations and strategic analytics frequently. As the pioneer of genetic testing for reproductive health, we offer unmatched expertise and the largest collection of laboratory tests. It is my pleasure to endorse the firm.


Bill Welch
, Chief Executive Officer, Trovagene, Inc. (TROV)

I am pleased to provide the highest endorsement for Berg Capital Markets, LLC (BCM). I have had the opportunity to work with Josh Berg for over 12 years and know him to be highly ethical and client focused. Mr. Berg has assembled an exemplary team that reflects his commitment to customers as a full service investor relations and analytics provider. I also enjoy and appreciate the quality service and professionalism at BCM and view BCM as a partner in building and messaging our growing organization.


James Levine, CEO, Verenium Corporation (NASDAQ:VRNM)

“From the outset, Josh took the time to really get to know our Company, to work together with us to identify our primary needs, and then to execute on those primary needs. Through both the investor targeting process and his work setting up investor meetings for Verenium’s management, it is clear that Josh has earned the trust of many institutional portfolio managers and analysts. It is clear to me that Josh’s connections are differentiated from other investor relations consultants, and it’s my pleasure to sincerely recommend Berg Capital Markets for any investor relations consulting that you might be considering.”

Jeff Black,
 CFO, Verenium Corporation (NASDAQ:VRNM)

“It is my distinct pleasure to recommend Josh Berg for any investor relations consultancy that you may be considering. Josh was introduced to me through one of his quality sell-side relationships. During his consultancy, Josh has proven himself over and over again through his strong work ethic and intelligent, thoughtful approach to everything he does. Josh has demonstrated a differentiated value proposition to Verenium. Contrary to most investor relations consultants, what Josh does is both real and measurable. It is clear to me that Josh has a vast number of long-term, quality, deep relationships with institutional and high-net worth investors. What is also clear to me is that Josh is quite capable of doing a number of other things within an investor relations role as well. I have grown to trust and rely on Josh for his insights and investor relations expertise. He is a valuable partner and is a pleasure to worth with thanks to his direct, honest nature. I can unequivocally recommend Josh for any investor relation capacity.”


The contents of this website: (i) do not constitute an offer of securities or a solicitation of an offer to buy securities, and (ii) may not be relied upon in making an investment decision related to any investment offering by Berg Capital Markets, LLC, or any affiliate, or partner thereof (“Berg”). Investment offerings and investment decisions may only be made on the basis of a confidential private placement memorandum issued by Berg Capital Markets, LLC, or one of its partner/issuers. Berg Capital Markets, LLC does not warrant the accuracy or completeness of the information contained herein.